The efficacy of levetiracetam for focal seizures and its blood levels in children

被引:17
作者
Iwasaki, Toshiyuki [1 ]
Toki, Taira [1 ]
Nonoda, Yutaka [1 ]
Ishii, Masahiro [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Pediat, Sagamihara, Kanagawa 2520374, Japan
关键词
Antiepileptic drug; Maintenance dosage; Optimal range; Seizure reduction rate; Side effect; DOUBLE-BLIND; ANTIEPILEPTIC DRUGS; REFRACTORY EPILEPSY; CHILDHOOD EPILEPSY; PROFILE; ONSET; PHARMACOKINETICS; TRIAL;
D O I
10.1016/j.braindev.2014.11.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aim: To evaluate the efficacy of levetiracetam (LEV) and the usefulness of measurement of its blood levels during the follow-up of patients with focal seizures. Methods: Twenty-four patients (13 cases without impairment of consciousness or awareness and 11 cases with them or evolving to a bilateral, convulsive seizure) treated with LEV had their peak blood levels measured. The blood concentrations were measured at 2 weeks, 1 year and 2 years after reaching the LEV maintenance dosage. The efficacy of LEV was evaluated with repeated blood sampling to determine the seizure reduction rate. The patients were classified as effective cases (seizure reduction rate > 50%) and ineffective cases (<= 50%). Results: In Japanese children treated with LEV, the dosage and blood level showed positive correlations. The blood levels were higher in effective cases than in ineffective cases at all time points (p < 0.05). In effective cases, the blood concentration was 23.26 +/- 6.88 mu g/mL (mean +/- SD) 2 weeks later, 23.59 +/- 8.23 mu m/mL 1 year later, and 24.46 +/- 7.57 mu g/mL 2 years later. However, the blood levels and efficacies showed positive correlations only at 2 weeks and 1 year later. No patients had any side effects. Conclusions: No precise definition of the therapeutic range was possible because of the incomplete correlation between the blood level and seizure frequency. Instead of a therapeutic range, we recommend an optimal range for LEV of 20-30 mu g/mL as a therapeutic target without any side effects. (C) 2014 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:773 / 779
页数:7
相关论文
共 25 条
[1]   Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy [J].
Ben-Menachem, E ;
Falter, T .
EPILEPSIA, 2000, 41 (10) :1276-1283
[2]   Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy [J].
Boon, P ;
Chauvel, P ;
Pohlmann-Eden, B ;
Otoul, C ;
Wroe, S .
EPILEPSY RESEARCH, 2002, 48 (1-2) :77-89
[3]   Levetiracetam for partial seizures - Results of a double-blind, randomized clinical trial [J].
Cereghino, JJ ;
Biton, V ;
Abou-Khalil, B ;
Dreifuss, F ;
Gauer, LJ ;
Leppik, I .
NEUROLOGY, 2000, 55 (02) :236-242
[4]   Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4-to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate [J].
Fountain, Nathan B. ;
Conry, Joan A. ;
Rodriguez-Leyva, Ildefonso ;
Gutierrez-Moctemma, Juvenal ;
Salas, Edubijes ;
Coupez, Rene ;
Stockis, Armel ;
Lu, Zhihong .
EPILEPSY RESEARCH, 2007, 74 (01) :60-69
[5]   Rapid onset of action of levetiracetam in refractory epilepsy patients [J].
French, J ;
Arrigo, C .
EPILEPSIA, 2005, 46 (02) :324-326
[6]   Levetiracetam in children with refractory epilepsy: Lack of correlation between plasma concentration and efficacy [J].
Giroux, Patricia C. ;
Salas-Prato, Milagros ;
Theoret, Yves ;
Carmant, Lionel .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2009, 18 (08) :559-563
[7]   Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures [J].
Glauser, T. A. ;
Ayala, R. ;
Elterman, R. D. ;
Mitchell, W. G. ;
Van Orman, C. B. ;
Gauer, L. J. ;
Lu, Z. .
NEUROLOGY, 2006, 66 (11) :1654-1660
[8]   Pharmacokinetics of levetiracetam in infants and young children with epilepsy [J].
Glauser, Tracy A. ;
Mitchell, Wendy G. ;
Weinstock, Arie ;
Bebin, Martina ;
Chen, Dion ;
Coupez, Rene ;
Stockis, Armel ;
Lu, Zhihong .
EPILEPSIA, 2007, 48 (06) :1117-1122
[9]   UCB L059, A NOVEL ANTICONVULSANT DRUG - PHARMACOLOGICAL PROFILE IN ANIMALS [J].
GOWER, AJ ;
NOYER, M ;
VERLOES, R ;
GOBERT, J ;
WULFERT, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 222 (2-3) :193-203
[10]   Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy [J].
Kanemura, Hideaki ;
Sano, Fumikazu ;
Tando, Tomoko ;
Sugita, Kanji ;
Aihara, Masao .
BRAIN & DEVELOPMENT, 2013, 35 (05) :386-391